SPOTLIGHT -
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
State of Science Summit- GU Cancers: Chaired by Dr. Chandler Park MD, FACP
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
State of Science Summit- Bladder/Prostate: Chaired by Alicia Morgans, MD, MPH
Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
CA-125 May Be the Key to Renal Medullary Carcinoma Treatment
Triplet Combinations Could Represent Next Frontier in Frontline Metastatic RCC
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC